Think Positive: Clovis Confident Of CHMP Okay For Rubraca

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

SC1802_Crossed Fingers_351834077_1200.jpg
Fingers crossed: Clovis expects good news from the CHMP in March • Source: Shutterstock

It is looking likely that a third PARP inhibitor will soon be available in Europe to patients with ovarian cancer with Clovis Oncology Inc.'s announcement that it expects a recommendation for approval for Rubraca (rucaparib) from the EU's regulators at the end of next month.

The company says that following a meeting with the European Medicines Agency's Scientific Advisory Group Oncology last week and an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.